ERT Further Enhances its Market-Leading Delivery Expertise
PHILADELPHIA (PRWEB) January 07, 2019 -- ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced the addition of Robert (Bob) Shambaugh to the role of Executive Vice President of Operations Delivery and Fulfillment.
Based in ERT’s Philadelphia office, Bob is responsible for developing and overseeing the strategic direction of ERT’s day-to-day operations, ensuring the company’s suite of proven eClinical solutions deliver the highest quality clinical trial data for use in the development of new medical products.
“Bob’s impressive track record of achieving superior levels of operational performance complements ERT’s expertise in managing our customer’s most complex challenges,” said James Corrigan, President and CEO of ERT. “We’re delighted to have him join us as we expand on our commitment to delivering the highest levels of customer satisfaction and continue to explore new, innovative ways to make clinical trials more efficient.”
Bob brings decades of delivering operational excellence to ERT, including extensive experience in operations, manufacturing, supply chain management, and strategic sourcing in the healthcare, aerospace, energy, and automotive industries. He joins ERT from Aerodyn Engineering, after having held a wide range senior leadership positions with Chromalloy, Sensata Technologies, and GE Healthcare.
“I’m very excited to add my experience to ERT’s knowledgeable leadership team at a time when so many pharmaceutical companies are facing mounting pressures to reduce clinical development costs and timelines,” said Bob. “I’m eager to jump right in to ensure our customers have the solutions and services they need to accelerate clinical development so that they can bring medical treatments to the patients who need them quickly, and with confidence.”
Visit ert.com/safety-efficacy/ for more information on how ERT’s eClinical solutions deliver high-quality clinical trial data to ensure reliable patient safety and compound efficacy measurement.
About ERT
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials. ERT’s solutions measure treatment efficacy, ensure patient safety, enable effective data integration and analytics, and deliver real-world insights so that its customers can move ahead with confidence. Since 2013, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs and CROs have relied on ERT solutions in 13,000+ studies, spanning more than three million patients to date. By identifying trial risks before they become problems, ERT enables its customers to bring clinical treatments to patients quickly ─ and with confidence.
For more information, go to ert.com or follow us on LinkedIn and Twitter.
Christine Tobin, ERT, http://www.ert.com, +1 4127194568, [email protected]
Share this article